{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:02:09Z","timestamp":1696291329802},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2011]]},"DOI":"10.2169\/internalmedicine.50.4572","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T10:08:59Z","timestamp":1302602939000},"page":"699-705","source":"Crossref","is-referenced-by-count":10,"title":["Open-Label Randomized Multicenter Selection Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir-Boosted Atazanavir to Efavirenz with Fixed-Dose Abacavir and Lamivudine"],"prefix":"10.2169","volume":"50","author":[{"given":"Miwako","family":"Honda","sequence":"first","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiyo","family":"Ishisaka","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Research Institute, National Center for Global Health and Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Tokyo Teishin Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"behalf of Japanese Anti-HIV-1 QD Therapy Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","first-page":"e33","volume":"12","author":"Lapphra K, Vanprapar N, Chearskul S","year":"2008","journal-title":"Int J Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1201-9712","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1468-1293.2008.00597.x","volume":"9","author":"Laureillard D, Prak N, Fernandez M,","year":"2008","journal-title":"HIV Med","ISSN":"http:\/\/id.crossref.org\/issn\/1464-2662","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-200501280-00011","volume":"19","author":"Ananworanich J, Moor Z, Siangphoe U","year":"2005","journal-title":"AIDS","ISSN":"http:\/\/id.crossref.org\/issn\/0269-9370","issn-type":"print"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012035"},{"key":"5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10096-010-0926-y","volume":"29","author":"Chowers M, Gottesman BS, Leibovici","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0934-9723","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Maggiolo F, Roat E, Pinti M, et al. Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. Antivir Ther 15: 51-59, 2010.","DOI":"10.3851\/IMP1483"},{"key":"7","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1086\/377609","volume":"37","author":"Tanuma J, Gatanaga H, Oka S, et al","year":"2003","journal-title":"Clin Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1058-4838","issn-type":"print"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07873-X"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sun HY, Hung CC, Lin PH, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 60: 599-604, 2007.","DOI":"10.1093\/jac\/dkm243"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1086\/595890"},{"key":"11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14740331003627458","volume":"9","author":"Rodriguez-Nóvoa S, Alvar","year":"2010","journal-title":"Expert Opin Drug Saf","ISSN":"http:\/\/id.crossref.org\/issn\/1474-0338","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010 Feb 19 (Epub), DOI:10.1097\/QAI.0b013e3181d05579","DOI":"10.1097\/QAI.0b013e3181d05579"},{"key":"13","unstructured":"13. United States Department of Health and Human Services. DHHS Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, May 2006. ."},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2006.22.744"},{"key":"15","unstructured":"15. Friis-Møller Nina, Reiss P, El-Sadr W, et al; D:A:D Study Group. Exposure to PI and NNRTI and risk of myocardial infarction: Results from the D:A:D Study, 13th conference on retrovirus and opportunistic infections. 2006 abstract 144."},{"key":"16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"Sabin CA, Worm SW, Weber R, et al","year":"2008","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"17","unstructured":"17. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treatment Reports 69: 1375-1381, 1985."},{"key":"18","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1086\/498069","volume":"192","author":"Gallant JE, Rodriguez AE, Weinberg","year":"2005","journal-title":"J Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0022-1899","issn-type":"print"},{"key":"19","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","volume":"361","author":"Sax PE, Tierney C, Collier AC, et a","year":"2009","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","volume":"23","author":"Smith KY, Patel P, Fine D, et al","year":"2009","journal-title":"AIDS","ISSN":"http:\/\/id.crossref.org\/issn\/0269-9370","issn-type":"print"},{"key":"21","unstructured":"21. BULLETIN NIAID Modifies HIV Antiretroviral treatment study combination therapy that includes ABC\/3TC found less effective in subgroup of antiretroviral-naïve individuals. http:\/\/www.niaid.nih.gov\/news\/newsreleases\/2008\/Pages\/actg5202bulletin.aspx (accessed on July 15 2010)."},{"key":"22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","volume":"43","author":"Clifford DB, Evans S, Yang Y, et al","year":"2005","journal-title":"Ann Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1310\/92VR-FP24-J8GA-B49Q","volume":"6","author":"Hawkins T, Geist C, Young B, et al","year":"2005","journal-title":"HIV Clin Trials","ISSN":"http:\/\/id.crossref.org\/issn\/1528-4336","issn-type":"print"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. van Luin M, Bannister WP, Mocroft A, et al; EuroSIDA Study Group. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir Ther 14: 75-83, 2009.","DOI":"10.1177\/135965350901400116"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Elzi L, Marzolini C, Furrer H, et al; Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 170: 57-65, 2010.","DOI":"10.1001\/archinternmed.2009.432"},{"key":"26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s15010-008-8010-6","volume":"37","author":"Torti C, Lapadula G, Antinori A, et","year":"2009","journal-title":"Infection","ISSN":"http:\/\/id.crossref.org\/issn\/0300-8126","issn-type":"print"},{"key":"27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00228-009-0763-z","volume":"66","author":"Josephson F, Andersson MC, Flamholc","year":"2010","journal-title":"Eur J Clin Pharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0031-6970","issn-type":"print"},{"key":"28","unstructured":"28. United States Department of Health and Human Services. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents-December 1, 2009. http:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL001419.pdf accessed on Jan 17 2011."},{"key":"29","unstructured":"29. European AIDS Clinical Society. Guidelines of Clinical Management and Treatment of HIV infected adult in Europe. Version 5, 2009. http:\/\/www.europeanaidsclinicalsociety.org\/guidelinespdf\/EACS-EuroGuidelines2009FullVersion.pdf accessed on Jan 17 2011."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/50\/7\/50_7_699\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T07:46:13Z","timestamp":1686037573000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/50\/7\/50_7_699\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.50.4572","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}